Does aging reduce hepatic LDL receptor–mediated clearance and raise circulating LDL particles?

The association between aging and elevated low-density lipoprotein (LDL) particles is well-supported by scientific evidence, specifically linking it to a progressive decline in the liver's ability to clear these particles via the LDL receptor (LDLR) pathway.

Clinical and metabolic evidence

Human kinetic studies using stable isotope tracers consistently demonstrate that aging is associated with a significant reduction in the fractional catabolic rate (FCR) of LDL particles. This means that as individuals age, LDL particles remain in the bloodstream for longer periods before being cleared by the liver.

• Clearance Rates: Research suggests that hepatic LDL clearance efficiency can decline by nearly 50% between early adulthood and age 65.
• Particle Accumulation: Because each LDL particle contains a single apolipoprotein B-100 (ApoB-100) molecule, the inability of the liver to clear these particles leads directly to an increase in circulating LDL particle concentration (LDL-P) and LDL cholesterol (LDL-C).
• Projected Increases: Computational models of human cholesterol metabolism indicate that age-related reductions in hepatic LDLR activity can contribute to an increase in plasma LDL-C of up to 116 mg/dL by age 65.

Mechanistic explanations

The primary driver of reduced clearance is not just a decrease in the production of LDL receptors, but an increase in their degradation and a failure in their recycling process.

• PCSK9 Activity: A central mechanism in aging is the upregulation of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). Circulating levels of PCSK9 tend to increase with age. PCSK9 binds to the LDLR on the surface of hepatocytes and redirects the receptor to the lysosome for degradation, rather than allowing it to recycle back to the cell surface.
• Receptor Availability: By increasing receptor degradation, PCSK9 significantly reduces the number of available receptors on the hepatocyte surface ready to bind and internalize LDL particles.
• Hepatocyte Senescence: Emerging research also points to hepatocyte senescence and shifts in the SREBP2 (Sterol Regulatory Element-Binding Protein 2) pathway as secondary contributors that further diminish the homeostatic control of cholesterol uptake in older age.

Bottom line

Aging directly impairs the hepatic LDL receptor pathway primarily through increased PCSK9-mediated degradation. This reduces the liver's capacity to remove ApoB-containing particles from the blood, resulting in the higher circulating LDL levels commonly observed in older adults.